Aurinia Pharmaceuticals (AUPH) Other Non-Current Liabilities (2019 - 2024)

Aurinia Pharmaceuticals' Other Non-Current Liabilities history runs 6 years deep, the most recent figure standing at $11.1 million for Q4 2024.

• Quarterly Other Non-Current Liabilities rose 1.9% year-over-year to $11.1 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $11.1 million (up 1.9% YoY) and the FY2024 annual result came in at $11.1 million, up 1.9% from the prior year.
• Other Non-Current Liabilities was $11.1 million for Q4 2024 at Aurinia Pharmaceuticals, up from $10.8 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $17.9 million in Q1 2021 and bottomed at $8.7 million in Q2 2023.
• A 5-year average of $13.7 million and a median of $12.3 million in 2023 frame the typical range for Other Non-Current Liabilities.
• Annual changes were most pronounced in 2020 — Other Non-Current Liabilities soared 162.57% — and 2023, when it plunged 46.56%.
• Aurinia Pharmaceuticals' Other Non-Current Liabilities stood at $16.3 million in 2020, then retreated by 1.81% to $16.0 million in 2021, then retreated by 23.75% to $12.2 million in 2022, then declined by 10.66% to $10.9 million in 2023, then increased by 1.9% to $11.1 million in 2024.
• Business Quant data shows AUPH's Other Non-Current Liabilities at $11.1 million in Q4 2024, $10.8 million in Q3 2024, and $10.9 million in Q2 2024.